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Abstract 
Genome-wide association studies (GWASs) aim to detect genetic risk factors for 
complex human diseases by identifying disease-associated single-nucleotide 
polymorphisms (SNPs). The traditional SNP-wise approach along with multiple testing 
adjustment is over-conservative and lack of power in many GWASs. In this article, we 
proposed a model-based clustering method that transforms the challenging high-
dimension-small-sample-size problem to low-dimension-large-sample-size problem and 
borrows information across SNPs by grouping SNPs into three clusters. We pre-specify 
the patterns of clusters by minor allele frequencies of SNPs between cases and 
controls, and enforce the patterns with prior distributions. In the simulation studies our 
proposed novel model outperform traditional SNP-wise approach by showing better 
controls of false discovery rate (FDR) and higher sensitivity. We re-analyzed two real 
studies to identifying SNPs associated with severe bortezomib-induced peripheral 
neuropathy (BiPN) in patients with multiple myeloma (MM). The original analysis in the 
literature failed to identify SNPs after FDR adjustment. Our proposed method not only 
detected the reported SNPs after FDR adjustment but also discovered a novel BiPN-
associated SNP rs4351714 that has been reported to be related to MM in another 
study. 
Introduction 
Genome-wide association studies (GWASs) aim to detect genetic risk factors for 
complex human diseases by identifying disease-associated single-nucleotide 
polymorphisms (SNPs). The most commonly-used approach in GWASs is the SNP-wise 
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approach, in which a test of association is performed for each SNP, and then the P-
values are adjusted for multiple testing. However, because of multiple testing 
adjustment to a huge number (> 1 million) of tests in GWAS, this approach often lacks 
power. Multiple testing adjustment uses no information other than P-values, which 
insufficiently models the relationships among SNPs, and need to be improved. 
     
To reduce the number of tests, SNP-set analysis has been proposed (e.g., Wu et al. 
2010[1]; Dai et al. 2013[2]; Lu et al. 2015[3]; Cologne et al. 2018[4]). The idea is to use 
SNP sets to replace individual SNPs. Hence, the number of tests can be reduced. 
However, it is challenging to define SNP sets. One approach is to define SNP sets 
based on existing biological knowledge. However, biological knowledge is subject to 
error. Poor quality of SNP-set can lead to low power (Fridley and Biernacka, 2011[5]). 
    
 Penalized regression approach has also been proposed in GWASs. For instance, linear 
mixed models (e.g., Kang et al. 2010[6]; Lippert et al. 2011[7]; Zhou and Stephens 
2012[8]) treat the effect of the SNP marker of interest as fixed, with the effects of all 
other SNP markers as normally distributed random effects. This process is repeated in 
turn for every SNP marker. However, it is a paradox to treat markers as fixed for 
inference but then otherwise as random to account for population structure for inference 
on association with other markers (Goddard et al. 2016[9]; Chen et al. 2017[10]). 
Bayesian hierarchical regression models treat the effects of all SNPs as random effects 
with either local priors or non-local priors (Mallick and Yi 2013[11]; Fernando and 
Garrick 2013[12]; Wang et al. 2016[13]; Chen et al. 2017[10]). Noticing that penalized 
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regression methods often lead to large number of false positives and Bayesian 
regression methods are computationally very expensive, Sanyal et al. (2018)[14] 
proposed a non-local prior based iterative SNP selection tool for GWASs, which 
enables borrowing information across SNPs and can utilize the dependence structure 
across SNPs. However, all of these methods are for quantitative outcomes (e.g., height) 
in GWASs.  
 
Several methods have been proposed to increase statistical power based on borrowing 
information across gene probes via mixture models. For example, Gamma-Gamma 
model (GG)[15], Log-Normal-Normal (LNN)[16], extended GG (eGG)[17], extended 
LNN (eLNN)[17], eLNN for paired data[18], and Marginal Mixture Distributions 
(GeneSelectMMD)[19] have been proposed for gene microarray data, and edgeR[20], 
DESeq[21, 22], and DESeq2 [23] have been proposed for next-generation sequencing 
(RNAseq) data. All these methods have been successfully applied to either gene 
microarray data analysis (continuous-scale data) or RNAseq data analysis (count data). 
However, to the best of our knowledge, no methods have been proposed to borrow 
information across SNPs (categorical variables with three levels of genotype) to analyze 
case-control GWAS data that have binary phenotype (cases vs. controls).  
     
In this article, we proposed a novel model-based clustering method for case-control 
GWASs (binary phenotype) by transforming the challenging high-dimension-small-
sample-size problem to low-dimension-large-sample-size problem. Specifically, we treat 
SNPs as “samples” and subjects as “variables” and aim to cluster SNPs to three 
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groups: (1) SNPs with minor allele frequencies (MAFs) higher in cases than in controls; 
(2) SNPs with MAFs lower in cases than in controls; and (3) SNPs with MAFs in cases 
same as in controls. For a given SNP, we assume its genotypes follow a multinomial 
distribution and the MAF follows a beta distribution. We also assume that the cluster 
proportions follow a Dirichlet distribution. In our method, we pre-specify the patterns of 
clusters by minor allele frequencies (MAFs) of SNPs between cases and controls, and 
enforce the patterns with the guide of prior distributions.  The proposed model-based 
clustering method can improve the power of detecting disease-associated SNPs by 
borrowing information across SNPs. For details, please refer to the METHODS Section.  
 
Our method is motivated by our investigation of the genetic risk factors of the 
bortezomib-induced peripheral neuropathy (BiPN) in treating Multiple Myeloma (MM) by 
using GWASs. MM is a type of cancer that causes a group of plasma cells (a type of 
white blood cell in the bone marrow that helps fight infections by making antibodies that 
recognize and attack germs) to be cancerous[24]. The MM cancer cells produce 
abnormal proteins that can cause complications that can damage the bones, the 
immune system, kidneys, and red blood cell. MM is the third most common blood 
cancer in the United States. Bortezomib is a first-in-class proteasome inhibitor to treat 
MM[25, 26]. However, Bortezomib has some side effects, such as the development of a 
painful, sensory peripheral neuropathy (PN)[27-29]. Bortezomib could induce 
neurotoxicity in neuronal cells by several mechanisms that lead to apoptosis[30]. The 
symptoms of the BiPN include neuropathic pain and a length-dependent distal sensory 
neuropathy with a suppression of reflexes. Due to BiPN, patients often discontinue 
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bortezomib treatment despite a good response to the therapy[31]. If we could identify 
patients at the risk of developing BiPN, physicians then can choose alternative 
therapies, such as using weekly, reduced-dose, or subcutaneous approaches. 
However, BiPN mechanisms are mostly unknown. It has been shown that a higher 
cumulative dose is likely to predict the increase of severity of BiPN[32, 33]. Pre-existing 
neuropathies, comorbidities (like diabetes mellitus) or myeloma-related peripheral nerve 
damage may also increase the risk of developing BiPN[34, 35]. Meregalli (2015)[36] 
provided a review of bortezomib-induced neurotoxicity. 
     
The inter-individual difference in the onset of BiPN indicates that genetics plays an 
important role. The candidate gene approaches have identified a few single nucleotide 
polymorphisms (SNPs) associated with the development of BiPN[28, 37-39]. For 
example, Broyl et al. (2010)[28] identified 20 BiPN-associated SNPs after examining 
3,404 candidate SNPs. The sample sizes in Broyl et al.’s (2010) study[28] are relatively 
small. Seven of the 20 SNPs were identified by comparing 13 grade 2-4 BiPN patients 
after one cycle of bortezomib treatment with 147 no-BiPN patients (rs2251660, 
rs4646091, rs1126667, rs434473, rs7823144, rs1879612, and rs1029871). The other 
13 SNPs were identified by comparing 49 grade 2-4 BiPN patients after two or three 
cycles of bortezomib treatment with 80 no-BiPN patients (rs1799800, rs1799801, 
rs2300697, rs1059293, rs2276583, rs189037, rs10501815, rs664677, rs664982, 
rs6131, rs1130499, rs4722266, and rs2267668). Corthals et al. (2011)[38] conducted a 
candidate SNP analysis with larger sample sizes than Broyl et al. (2010)[28] did, which 
revealed associations with BiPN based on 2,149 SNPs using a discovery set with 238 
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samples and a validation set with 231 samples. However, after adjusting for multiple 
testing, no significant SNPs were identified. Favis et al. (2011)[39] conducted several 
survival analyses based on 2,016 SNPs and identified five BiPN associated SNPs 
(rs4553808, rs1474642, rs12568757, rs11974610, and rs916758) in the discovery set 
(139 samples) after adjusting for multiple testing. However, none of these five SNPs 
were validated in the validation set (212 samples).  
     
GWAS could be used to unbiasedly identify genetic variants that will have a direct or 
indirect effect on drug sensitivity[29]. NHGRI GWAS Catalog [40, 
41](https://www.ebi.ac.uk/gwas/) lists only two GWA studies that have been performed 
to identify SNPs associated with BiPN for MM patients. The first GWAS was performed 
by Magrangeas et al. (2016)[29], who identified one BiPN-associated SNP (rs2839629) 
based on 370,605 SNPs using a discovery set (469 samples) and a validation set (114 
samples). However, results did not reach a genome-wide significance level. The second 
GWAS was conducted by Campo et al. (2018)[42], who identified four BiPN-associated 
SNPs (rs6552496, rs12521798, rs8060632, and rs17748074) based on 646 samples. 
Again, the results did not reach a genome-wide significance level. Moreover, each of 
the four lists of BiPN-associated SNPs listed above (the 20 SNPs identified by Broyl et 
al. (2010)[28]; the five SNPs identified by Favis et al. (2011)[39]; the one SNP identified 
by Magrangeas et al. (2016)[29]; and the four SNPs identified by Campo et al. 
(2018)[42]) was not replicated in the other three studies.  
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Note that the existing two GWASs[28, 42] used SNP-wise approaches (i.e., performing 
one association test per SNP), which over-adjusts for multiple tests due to insufficiently 
modeled relationships among SNPs (i.e., true FDRs/FWERs are smaller than nominal 
FDR/FWER levels), and hence are not powerful enough when sample sizes are 
relatively small. Therefore, the missing heritability[43] of BiPN could be due to less 
powerful statistical methods. Novel statistical methods are needed, they could borrow 
information across SNPs and better control FDR at nominal levels than the traditional 
over-conservative multiple testing adjustment approaches.  
     
     
Our novel method for SNP discovery is a model-based clustering approach. In our 
method, information can be shared across SNPs by grouping SNPs into three clusters. 
We pre-specify the patterns of clusters by minor allele frequencies (MAFs) of SNPs 
between cases and controls, and enforce the patterns with the guide of prior 
distributions. Using simulation studies and re-analysis of real data from Magrangeas et 
al. (2016)[29], we demonstrated that our method out-performs traditional approaches. In 
particular, compared to SNP-wise approaches, our method better controls FDR at a 
nominal level, and therefore it has a better sensitivity. 
Results 
Results of simulation studies 
We conducted simulation studies to compare the performance of our model-based 
clustering method with the SNP-wise approach (e.g., logistic regression followed by 
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multiple testing adjustment ). For our method, data analysis of each simulated dataset 
uses two different ways to choose values of hyper-parameters of the prior distributions 
for MAFs (obtained from either truncated Beta(2,5) or empirical distribution via moment 
matching approach). Details on the design of simulation studies and the choice of 
hyper-parameters for MAF priors are explained in the ‘METHODS’ Section.  
 
Figure 1 shows the simulation results for 500,000 SNPs with 200 effective SNPs using 
four different MAF distributions for data generation and two different sample sizes. The 
results of comparing sensitivity are presented in the right panel of the figure, where the 
boxplots represent differences between our method and the SNP-wise approach, which 
were obtained by considering sensitivity of our method using truncated Beta(2, 5) 
(colored in light grey) or empirical distribution (colored in dark grey) minus sensitivity of 
the SNP-wise approach for each simulated dataset. Our method outperformed the SNP-
wise approach in sensitivity, since all of the boxes are on the right-hand side of the 
vertical dashed line 0. Boxplots in the middle panel show FDRs for the SNP-wise 
approach, our method using truncated Beta(2, 5) for analysis, and our method using 
empirical estimates for analysis. FDR of detected SNPs using our method is much 
closer to the nominal level 0.05 (vertical dashed line) than the SNP-wise approach for 
every setting presented in the figure. We conducted Wilcoxon signed rank tests to 
compare our method and the SNP-wise approach on |FDR-0.05| and on sensitivity for 
the settings in Figure 1. All of tests were significant with small P-values (< 0.0093; see 
Supplementary Table S2), confirming that the differences observed from the parallel 
boxplots are statistically significant. By comparing the top four rows with the bottom four 
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rows in Figure 1, we also observed that the improvement of our method over the 
traditional approach becomes more prominent when the sample size of the study was 
smaller. 
     
In all other settings of simulations studies, compared with the traditional approach, our 
method consistently showed higher sensitivities and FDRs closer to the nominal level of 
0.05 (see Figures S1-S5 in Supplementary File S4). Results from Wilcoxon signed rank 
tests for these settings are also provided in Supplementary Table S2 with all P-values 
smaller than the significance level 0.05. Even when we incorrectly specified the prior 
distributions for analysis (e.g.,  when we used different values between data generation 
and data analysis for hyper-parameters 𝛼 and 𝛽), our method still outperformed the 
traditional SNP-wise approach (see rows 2-4 and 6-8 in Figure 1 and S1-S5 in 
Supplementary File S4).   
     
In summary, our method performed better in discovering effective SNPs associated with 
the outcome. The traditional SNP-wise approach over-penalizes multiple testing and 
insufficiently utilizes the shared information among SNPs. When targeting on the 
nominal FDR level 0.05, the traditional approach always had a true FDR less than the 
nominal level, which reduces sensitivity.  
Results of real data analysis 
From the Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/), we 
downloaded two SNP datasets (GSE65777 and GSE66903) that were used by 
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Magrangeas et al. (2016)[29] to evaluate the genetic effects on developing severe 
bortezomib-induced peripheral neuropathy (BiPN). The discovery dataset (GSE65777) 
contains 909,622 SNPs and 469 newly-diagnosed patients with multiple myeloma 
treated with bortezomib. The goal was to compare SNP genotypes from 155 patients 
with grade ≥ 2 BiPN with those from 314 MM patients with grade 1 BiPN or no BiPN. 
The validation dataset (GSE66903) contains 795,734 SNPs and 116 MM patients 
treated with bortezomib. The goal of the validation study was to compare 41 
bortezomib-treated grade ≥ 2 BiPN patients with 75 bortezomib-treated control patients. 
A genome-wide association study of the 370,605 SNPs after quality control (QC) on the 
discovery data GSE65777 was conducted by Magrangeas et al. (2016)[29]. In our 
analysis, 247,372 SNPs that passed our QC criteria, which is basically the same as the 
criteria used by Magrangeas et al. (2016)[29] except for two minor changes (see 
Section D of Supplementary File S3 for details on our QC steps). 
    
We first re-analyzed discovery data (GSE65777) with SNP-wise approaches. The 
association between the outcome and each SNP was tested by both logistic regression 
and the Cochran-Armitage test. No SNP is significant after multiple testing adjustment 
at FDR level 0.1. Note SNPs reported by Magrangeas et al. (2016)[29] were not 
detected with the genome-wide threshold 5x10-8, but with a much larger P-value 
threshold 10-5.   
     
We then analyzed the discovery dataset (GSE65777) with our method. The values for 
hyper-parameters α and β were set to their moment estimates from SNP data. Table 1 
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lists the significant SNPs detected based on the combinations of settings of two different 
pseudo counts and two targeted FDR levels. Since all significant SNPs detected by our 
method have been adjusted for FDR, our method is more powerful in detecting SNPs 
than the traditional approach. 
     
We next analyzed the validation dataset (GSE66903) to validate the significant SNPs  in 
Table 1, using exactly the same approach as Magrangeas et al. (2016)[29]. The SNP 
rs2839629 can be validated (with a P-value of 0.0324 after multiple adjustment 
controlling FDR level at 0.1), which is detected in discovery dataset using a pseudo 
count of (3, 3, 3) and a detection rule of FDR7 < 0.1 (Table 2).  
     
We tried analyzing the data with a different pseudo count (5, 5, 5), and get exactly the 
same results as using (3, 3, 3). When we used a stronger prior by increasing the 
pseudo count to (20, 20, 20), we obtained six SNPs that were assigned to the clusters 
of significant SNPs. Among the six SNPs, rs4351714 is a possible novel SNP to BiPN, 
which locates in the intron region of gene KDM5B and is proved to be associated with 
multiple myeloma[44, 45], but no existing literature has reported that rs4351714 is 
associated to BiPN. KDM5B is known as a member of the KDM5 subfamily that serves 
as transcriptional co-repressors, specifically catalyzing the removal of all possible 
methylation states from lysine 4 of histone H3  (H3K4me3/me2/me1). It has been linked 
to control of cell proliferation, cell differentiation and several cancer types. By employing 
a KDM5 enzymes inhibitor in myeloma cells, a higher quartile of KDM5B expression 
was found to be associated with shorter overall survival in myeloma patients[45].  
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Discussion 
We proposed a novel model-based clustering method to characterize the association 
between SNPs and a binary outcome in case-control genome-wide association studies. 
Compared with the traditional SNP-wise approach, it has advantages in efficiently 
utilizing the data, since we account for the relationships among SNPs in the model. Our 
novel method has two major advantageous features. 
   First, compared to the traditional method, our method provides more power to detect 
true SNPs associated with the outcome and better controls FDR at a nominal level 
without an over-conservative penalty from multiple testing adjustment. In the traditional 
SNP-wise approach, an association between the outcome and each SNP is tested 
separately, and then their P-values are adjusted for multiple testing. The multiple testing 
adjustment is purely based on P-values, which insufficiently utilizes the relationship 
among SNPs. In contrast, we group SNPs into clusters according to the pattern of their 
MAFs, allowing SNPs with similar patterns to share information with each other. The 
advantage of this feature of our method is demonstrated in both simulation studies and 
the re-analysis of the real data from a study on patients with multiple myeloma treated 
with bortezomib.  
     
Second, our model-based clustering method can handle millions of SNPs, which makes 
it tractable to “simultaneously” model a huge number of SNPs from the ultra-high 
dimensional GWAS data. Though the model is complex and involves millions of 
parameters, making the algorithm of model fitting quite challenging to implement, we 
integrate out the nuisance parameters (i.e., remove nuisance parameters from model 
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likelihood by averaging likelihood over the distribution of nuisance parameters). By only 
dealing with the essential parameters in the model fitting process, we make the 
algorithm feasible without losing information. 
     
Note that our novel model-based clustering method is different from the standard 
clustering methods. Standard clustering methods are an unsupervised learning method 
that discovers patterns freely from data. In contrast, supervised learning methods train 
models with both outcomes and predictors. Our method is in between. We specify 
cluster structures and enforce characteristics of each cluster by model priors, but we do 
not have true cluster memberships as the outcome to train the model. So we call our 
method a pseudo-supervised learning approach.  
     
In our pseudo-supervised learning approach, the prior modeling is the key component, 
which regulates SNPs into the correct clusters. In the machine learning literature, 
regularized regression models (e.g., Lasso and Elastic Net) always have their Bayesian 
equivalent counterpart (Bayesian Lasso[46] and Bayesian Elastic Net[47]). In these 
Bayesian approaches, shrinkage priors are used to achieve the equivalent penalty 
effect in regularized regressions. We adopt this idea and let the prior distributions guide 
the discovery of the patterns. In our model, the number of clusters is fixed, and the 
pattern of each cluster is described and enforced by the prior distributions.  
     
Using the same validation approach as in Magrangeas et al. (2016)[29], we validated 
the same SNP identified by Magrangeas et al. (2016)[29]. No more SNPs were 
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validated partly due to the inconsistency of signals between the discovery dataset and 
the validation dataset. First, not many SNPs have strong signals in both studies. See 
Table (a) in Supplementary File S5 where we ranked SNPs by raw P-value from 
smallest to largest. Among the top 1000 ranked SNPs in the discovery dataset with 
smallest raw P-values, only 30 SNPs have a raw P-value <0.05 for the validation data 
(see Table (b) in Supplementary File S5). Also, the ranks of these 30 SNPs are quite 
low in the validation set. Second, many SNPs have signals from opposite directions 
between the discovery set and the validation set. Among the top 1000 SNPs, 513 of 
them have opposite sign of MAF difference between cases and controls in the two 
datasets (Table (a) in Supplementary File S5). This means more than half of the top-
ranked SNPs are risk factors in one study but protective factors in another study. 
Among the 30 SNPs with reasonably strong signals in both studies, as mentioned 
above, nine SNPs showed opposite directions of MAF difference between cases and 
controls. 
Conclusion 
Genome-wide association studies (GWASs) aim to detect genetic risk factors for 
complex human diseases by identifying disease-associated single-nucleotide 
polymorphisms (SNPs). We developed a novel method for SNP discovery based on 
model-based clustering, which can also be considered as a pseudo-supervised machine 
learning approach. We compared our method with the traditional SNP-wise approach 
through simulation studies and a real data analysis. The traditional SNP-wise approach 
is over-conservative since its adjustment for multiple testing is purely based on P-
values, insufficiently accounting for the relationship between SNPs. Therefore, its true 
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FDR is always less than the nominal level and has less power to detect true signals. In 
comparison, our method can better control FDR at nominal level and detect more 
effective SNPs. In addition, our method simultaneously models all SNPs but makes 
computing feasible by integrating out nuisance parameters from the model.  
     In the re-analysis of the real data from Magrangeas et al. (2016)[29], the traditional 
method failed to detect any significant SNP after FDR adjustment. In contrast, our 
proposed method not only detected effective SNPs at the genome-wide significance 
level, which were reported in Magrangeas et al. (2016)[29] with a much larger P-value 
threshold than the genome-wide significance level, but also identified a novel BiPN-
associated SNP rs4351714 that has been proven to be associated with multiple 
myeloma. 
In summary, our method outperforms the traditional SNP-wise approach in SNP 
discovering from case-control GWAS.  
Methods	
Notations and 3-cluster mixture models 
Suppose we measure genotypes of G SNPs for n:	MM patients with BiPN (cases) and n<	MM patients without BiPN (controls). Our goal is to identify a subset of SNPs that are 
significantly associated with the risk of developing BiPN. For each SNP, we code its 
genotype as: 0 minor allele (wild-type homozygote), 1 minor allele (heterozygote), and 2 
minor alleles (mutation homozygote). We assumed Hardy Weinberg Equilibrium (HWE) 
for each SNP. Then the genotype frequencies of a SNP can be expressed as functions 
of the Minor Allele Frequency (MAF) θ: Pr(genotype=0) = (1 − θ)?, Pr(genotype=1) = 
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2θ(1 − θ), and Pr(genotype=2) =θ?. If a SNP has significantly different MAFs between 
cases and controls, then this SNP is associated with the risk of developing BiPN.  
     
We assume that there are three clusters of SNPs: (1) no effect cluster: cluster of SNPs 
having similar MAF between cases and controls (denoted as cluster 0);  (2) positive 
effect cluster: cluster of SNPs having significantly higher MAF in cases than in controls 
(denoted as cluster +);  and (3) negative effect cluster: cluster of SNPs having 
significantly lower MAF in cases than in controls (denoted as cluster −). That is, a MM 
patient with minor alleles of any SNP in cluster + tends to develop BiPN after receiving 
Bortezomib (i.e., having positive tendency in developing BiPN), while a MM patient with 
minor alleles of any SNP in cluster – tends to be protective from developing BiPN (i.e., 
having negative tendency in developing BiPN). SNPs in cluster 0 do not affect 
developing BiPN. 
    
 We use vectors of binary latent variables to describe the unknown cluster memberships 
of SNPs. For a given SNP g, its cluster membership can be expressed as 𝐳𝐠 =FzH,I, zH,J, zH,KL. Let zH,M = 1 indicate that SNP g belongs to cluster k, and zH,M = 0 
otherwise, where k = 0,+,− is the index of clusters. Here the indicators must satisfy ∑ zH,M = 1M∈{I,J,K} . Let 𝛑 = (πI, πJ, πK), satisfying ∑ πM = 1M∈{I,J,K} ,  be the proportion of 
SNPs in three clusters, which is called a mixture proportion. So the cluster membership zH follows a multinomial distribution as	PrFzHW𝛑L = Multinomial(1,𝛑) = 	∏ πM_`,a 	M∈{I,J,K} . 
We assume a Dirichlet prior Dir(𝐛) on 𝛑, 𝐛 = (bI, bJ, bK). Values of 𝐛 can be interpreted 
as pseudo count [48, 49] for each cluster.  
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The primary objective of the data analysis is to estimate the posterior distribution of zH 
given all observed SNP data and values of all model parameters, which will be used for 
the inference about which SNPs are significantly associated with the outcome. 
    
 What we described above is mixture models with three components. Next, we discuss 
in details about how the mixture models can be derived from mixture of Bayesian 
hierarchical models by modeling different patterns of the relationship between SNPs 
and binary outcomes of case-control status inside each cluster. 
Model and prior of genotype and MAFs  
For a given SNP g of patient i under condition d, we denote its genotype and minor 
allele frequency (MAF) in cluster k as SH,f,g and θH,f,M respectively, where d = x (case) or y	(control), g = 1, …, G,  i = 1, …, nf, and k=0,+,−. We modeled the distribution of the 
genotype SH,f,g of SNP g by the following multinomial distribution:  
g(SH,f,g|θH,f,M) = 	Multinomialk1, lθH,f,M?, 2θH,f,MF1 − θH,f,ML, (1 − θH,f,M)?m	n              (1) 
Note for SNPs in cluster 0, we have θH,:,I = θH,<,I; For SNPs in cluster +, we have θH,:,J 	> θH,<,J; and for SNPs in cluster −, we have θH,:,K < θH,<,K. These conditions will 
be enforced by prior distributions of MAF discussed below. 
     
Patterns of MAFs in different clusters can be distinguished and enforced by different 
prior distributions. Shared prior distributions of MAFs allow them to borrow strength from 
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each other. If a SNP has no effect on the outcome, it should have the same MAF in 
cases and controls. Hence, we use the same conjugate prior for both cases and 
controls: θH,f,I~	Beta(α, β). We denote its Probability Density Function(PDF) as h(∙), and 
use this PDF to help construct PDFs of the prior distributions for the other two clusters.     
     
For a SNP	in cluster +, i.e., SNPs having larger MAF in cases than in controls, we 
define a “half-bell shape” prior which enforces patterns of cluster + with probability 1. 
We assign a bivariate prior (θH,:,J, θH,<,J) with PDF	2hFθH,:,JLh(θH,<,J)I(θH,:,J > θH,<,J), 
where I(a) is the indicator function taking value 1 if a >0, and value 0 otherwise. Note in 
this PDF, the term hFθH,:,JLh(θH,<,J) can be considered as a “bell shape” bivariate 
distribution of independently and identically distributed (i.i.d.) variables θH,:,J and θH,<,J. 
The indicator function I(θH,:,J > θH,<,J) enforces the constraint θH,:,J > θH,<,J with 
probability 1. It “flattens” half of the bivariate distribution to change the shape into “half-
bell”, which makes a PDF of θH,:,J and θH,<,J satisfy our constraints with probability 1. 
The constant “2” in prior PDF ensures it is a proper PDF (i.e., integrates to 1). Similarly, 
For a SNP	in cluster −, we use the other “half-bell” prior by assuming a bivariate prior 
(θH,:,K, θH,<,K) with PDF 2hFθH,:,KLh(θH,<,K)I(θH,:,K < θH,<,K).   
    In GWASs, the set of parameters {θH,f,M} contains huge numbers of elements due to a 
large number of SNPs to be considered. Note that all {θH,f,M} are nuisance parameters, 
since they are not used for final inference of association between SNPs and outcomes. 
Hence, we integrate out all nuisance parameters {θH,f,M} from the model by averaging 
the complete likelihood over their prior distributions (more details in Section A of 
Supplementary File S3). Marginalization reduces a huge number of unnecessary 
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parameters from our model likelihood, and thus it makes model fitting feasible and more 
tractable.  
Choice of values for hyper-parameters 
    Our method is robust for different settings of hyper-parameters, as long as the choice 
of their values is not extremely unreasonable. More details are given in simulation 
studies.  
    The hyper-parameters α	and β are estimated by the moment matching approach 
based on the distribution of MAFs (detailed formulas are given in Section C of 
Supplementary File S3). In practice, if GWAS data contain a sufficient amount of SNPs 
as well as patient samples, we can estimate an empirical distribution of MAFs from all 
observed SNPs. When the dataset is not rich enough, we recommend using the left-
truncated Beta distribution Beta(2, 5). The distribution Beta(2, 5) is estimated from the 
distribution of MAF provided by Keinan et al. (2007)[50]. The truncated range is from the 
minimum MAF observed in the SNP data after quality control to 0.5. Note that both 
empirical distribution and the truncated Beta(2, 5) need to be approximated by a Beta 
distribution using the moment matching approach, which we call a Beta-approximation. 
This approximation can greatly speed up computation by using a conjugate prior. The 
detailed algorithm about calculation of (α, β) in these two situations is given in Section C 
of Supplementary File S3. Even if parameters are incorrectly specified, our method still 
can achieve better performance compared to the traditional SNP-wise approach (shown 
in simulation studies). 
    Values of the hyper-parameters (bI, bJ, bK) in Dirichlet prior can be assigned as small 
integers, e.g., (3, 3, 3), which is equivalent to a weak prior. Changing it to other small 
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integers (e.g., using (5, 5, 5)) will not affect final results. Using a very strong prior, e.g., 
(50, 50, 50), will change results of our analysis. Such large values can only be used if 
such belief is supported by prior biological knowledge.  
Graphical summary of proposed model-based clustering method  
Our model-based clustering method can be regarded as a mixture of Bayesian 
hierarchical models. Figure 2 shows the directed acyclic graphic of our mixture of 
Bayesian hierarchical models. The shaded areas on the left and right sides of the figure 
contain information in cases and controls respectively. Cases and controls are linked by 
the shared information displayed in the center part of the figure.  
Inferences, the decision rule for calling significant SNPs 
Calling which SNPs are significantly associated with the outcome is equivalent to 
assigning SNPs to cluster + or cluster −. The decision is made based on the posterior 
probability of a cluster[51]. 
     
Conditional on all observed data and hyper-parameters in the prior, we derive the 
posterior probability of cluster membership (also called “responsibility” in the machine 
learning community) using Bayesian theorem as 
γH,M = PrFzH,M = 1|SH, π, α, βL = uavaFw`|x,yL	∑ uzvzFw`|x,yLz∈{{,|,}}                             (2)              
where ξMFSH|α, βL is the marginal density of genotypes of the g-th SNP in the k-th cluster 
of all patients. (derivation on the marginal density ξM is given in Section A of 
Supplementary File S3).  
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To estimate the responsibilities γH,M, we first apply the EM algorithm to estimate the 
model parameters, mixture weights πM, and then plug the estimated model parameters 
into Formula (2). See Section B of Supplementary File S3 for details on the 
implementation.  
     
A straightforward decision rule about cluster membership is to assign each SNP to the 
cluster with the highest posterior probability, i.e., assign SNP g to the cluster 
corresponding to the largest value of γH,I, γH,J, and γH,K. 
     
An alternative is to assign a SNP to effective clusters (+ or −) if its responsibility of 
coming from cluster + or − is greater than a threshold τ. Following Yuan and 
Kendziorski (2006)[52], the value of τ can be specified to achieve a desired level of 
false discovery rate (FDR) given as follows[53]: 
FDR7 = ∑ `,{k`:`,|,	`,}nf{H:`,|,	`,}}                   (3)              
where “card{set}” means the number of elements in “set”. 
     
The second approach is preferred in most applications, since controlling FDR of 
detected SNPs is often desired for genomic studies. Users can decide which decision 
rule to use based on their specific applications. 
Design of simulation studies 
	 23	
We conducted simulation studies to compare the performance of our model-based 
clustering method with the SNP-wise approach (e.g., logistic regression followed by 
multiple testing adjustment). We generated datasets using different settings, by varying 
the combination of factors, including sample sizes (total 200 or 1000 with half cases and 
half controls), number of SNPs (1000, 20000, 500000), and various mixture proportions 𝛑. Details of multiple settings of simulation studies are given in Supplementary Table 
S1. 
     
In addition, to investigate the robustness of our method against the misspecification of 
the MAF prior, we used four settings of truncated beta distribution Beta(α, β) with the 
range [0.05, 0.5] for data generation. The four settings included truncated Beta(2, 5), 
which was also used in data analysis; truncated Beta(2, 4) and Beta(1.5, 3.5) 
distributions with a shifted mode to the right and left-hand side compared to Beta(2, 5) 
respectively; and truncated Beta(1.5, 5.5) with a sharper peak than Beta(2, 5). The last 3 
settings were used to investigate the performance of our method when MAF priors were 
incorrectly specified. All these four prior distributions were truncated to the range (0.05, 0.5), which ensured the MAFs of simulated SNPs were always greater than 0.05 
and smaller than 0.5. 
     
For each combination of settings above, we simulated 100 datasets. For every 
simulated dataset, we analyzed it using three approaches: (1) the traditional SNP-wise 
approach; (2) our method with prior of MAFs set as the Beta-approximation of truncated Beta(2, 5); and (3) our method with prior of MAFs set as the Beta-approximation of 
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empirical MAF distribution estimated from simulated SNP data (see Section C of 
Supplementary File S3). 
     
In data analysis, some initial values need to be specified to conduct the EM algorithm. 
We used raw p-values from the SNP-wise approach to specify initial cluster 
membership (SNPs with raw P-value smaller than 0.05 and different estimated MAF in 
cases/controls were initially classified into cluster +/−, while other SNPs were initially 
classified into cluster 0), and then we calculated initial values of 𝛑 based on initial 
cluster memberships. Dirichlet distribution with concentration parameter 3 (i.e., Dirichlet(3, 3, 3)) was used as the (weak) prior distribution for 𝛑.  
Comparison criteria in simulation studies 
Two criteria were used to compare our method with the SNP-wise approach in the 
simulation studies: FDR and sensitivity. Unlike real data analysis, actual FDR of 
analyses can be calculated in the simulation studies, since the truth of effective SNPs is 
known in these studies. We calculated actual FDR as the proportion of truly non-
effective SNPs among all SNPs called as significant by data analysis. Both our method 
and the traditional approach targeted FDR to be controlled at a level of 0.05, thus the 
successful method should have the actual FDR closer to 0.05. Sensitivity is defined as 
the proportion of SNPs detected significant among truly effective SNPs. Higher 
sensitivity means the method is more powerful. 
    Note that specificity is usually evaluated together with sensitivity. We did not report 
specificity in this article since both FDR and 1−specificity are measures of rate of type I 
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error (false positive rate). FDR is much more popularly used in genomic studies. Hence, 
we decided to control FDR instead of specificity.  
Data availability 
The two GWAS datasets are downloaded from the Gene Expression Omnibus (GEO) 
(https://www.ncbi.nlm.nih.gov/geo/) with accession IDs GSE65777 and GSE66903. We 
are wrapping our codes into an R package, called “BayesGWAS", and will submit to 
Bioconductor soon. 
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Tables 
Table 1. Significant SNPs detected by our method based on the discovery dataset 
(GSE65777). 
Pseudo count FDR7 Detected SNPs 
 
(3,3,3) 
< 0.1 rs10862339  rs1344016  rs2839629* < 0.05 rs10862339  rs1344016 
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(20,20,20) 
 < 0.1 rs10862339  rs1344016  rs2414277 rs2839629*  rs4351714**  rs4776196 < 0.05 rs10862339  rs1344016 
The SNP labeled with ‘*’ is the only SNP reported by Magrangeas et al. (2016)[29] as 
validated SNP, the SNP labeled with ‘**’ is a novel SNP detected by our method, and all 
other SNPs in the table are reported by Magrangeas et al. (2016)[29] in discovery data, 
but not validated in replication data.	
Table 2. Validation results for SNPs listed in Table 1. One-sided logistic 
regression with permutations followed by FDR adjustment for the validation set 
(GSE66903). 
SNP_ID Odds ratio P.raw P.permutation P.FDR 
rs10862339 0.98 (0.57-1.69) 0.4662 0.4783 0.4783 
rs1344016 1.05 (0.59-1.86) 0.4329 0.425 0.4783 
rs2839629 2.02 (1.12-3.65) 0.0096 0.0108 0.0324 
P.raw: raw P-values from one-sided logistic regression; P.permutation: P-values 
determined by permutation; P.FDR: permuted P-values after FDR adjustment. 
Figure legends 
Figure 1. Simulation results for 500,000 SNPs with 200 effective SNPs using four 
different MAF distributions for data generation and two different sample sizes 
respectively. The upper and lower four rows contain results of simulated data with 200 
samples and 1,000 samples respectively. The left panel shows truncated MAF 
distributions for data generation (solid line) and prior distributions for analysis 
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(approximated beta distributions via the moment matching: dashed lines are Beta-
approximations of truncated Beta(2, 5) and dotted lines are Beta-approximations of 
empirical distributions estimated from data). The middle panel shows boxplots for FDR 
and the vertical dashed line represents the nominal level (0.05). The right panel shows 
boxplots for paired difference of sensitivity between our method (using truncated Beta(2, 5) or empirical distribution for analysis) and the SNP-wise approach, and the 
vertical dashed line represents 0 (i.e., same performance between our method and the 
SNP-wise approach). White boxes represent the SNP-wise approach, light grey boxes 
represent our method using truncated Beta(2, 5) for analysis, and dark grey boxes 
represent our method using empirical distributions for analysis.  
Figure 2. Directed acyclic graph representation of our model-based clustering 
method. Observed data (SNP genotypes), cluster memberships, MAFs, and mixture 
proportions are denoted by S, z, θ, and π respectively. Plain solid rectangles represent 
observations. Diamonds represent latent variables of unknown cluster membership. 
Plain solid circles indicate model parameters to be estimated, while dashed circles 
represent nuisance parameters to be integrated out from the model likelihood by 
marginalization. Gray-filled circles represent pre-specified hyper-parameters.  
Supplementary information 
Supplementary Table S1: Different settings to generate data for both 200-sample 
and 1000-sample simulations. In data analysis, for prior MAF distribution, we used 
both truncated Beta(2,5) and empirical distribution estimated from MAFs of all SNPs in 
each simulated data. Note all these prior MAF distributions used for data analysis were 
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approximated by a Beta distribution via the moment matching. Truncated Beta(2,5) was 
approximated by Beta(3.29,9.56). 
Supplementary Table S2. P-values from Wilcoxon signed rank tests between our 
method and the SNP-wise approach on sensitivity and |FDR-0.05| for all settings 
of our simulation studies. 
Supplementary File S3. Supplementary materials and methods. Details for 
marginalization, EM implementation, moment matching, and QC for real data analysis. 
Supplementary File S4. Simulation results for different SNP sizes with different 
numbers of effective SNPs using 4 different MAF distributions for data generation 
and 2 different sample sizes respectively. Includes Figures S1-S5. In each figure, the 
upper and lower 4 rows contain results of simulated data with 200 samples and 1,000 
samples respectively. The left panel shows truncated MAF distributions for data 
generation (solid line) and prior distributions for analysis (approximated beta 
distributions via the moment matching: dashed lines are Beta-approximations of 
truncated Beta(2,5) and dotted lines are Beta approximations of empirical distributions 
estimated from data). The middle panel shows boxplots for FDR and the vertical dashed 
line represents the nominal level (0.05). The right panel shows boxplots for paired 
difference of sensitivity between our method (using truncated Beta(2,5) or empirical 
distribution for analysis) and the SNP-wise approach, and the vertical dashed line 
represents 0 (i.e., same performance between our method and the SNP-wise 
approach). White boxes represent the SNP-wise approach, light grey boxes represent 
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our method using truncated Beta(2,5) for analysis, and dark grey boxes represent our 
method using empirical distributions for analysis.  
Supplementary File S5. Additional information on datasets GSE66903 and 
GSE65777.  Two subtables are included. S5 Table (a) contains the top 1000 ranked 
SNPs in the discovery set with smallest raw P-values and S5 Table (b) contains the 30 
SNPs that also have a raw P-value <0.05 for the validation set. 
 
